Search
Human papillomavirus type 52 L1 capsid protein antigen
go.drugbank.com/drugs/DB10313ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigational] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma. … Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341
Etodolac
go.drugbank.com/drugs/DB00749ApprovedInvestigationalVet approvedEtodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of sig...
Felodipine
go.drugbank.com/drugs/DB01023ApprovedIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction.
Products: FELODIPIN 2.5MG RET HEU NAGRO100
go.drugbank.com/drugs/DB04998InvestigationalAGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells.
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label].
Synonyms: 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamideMUC1 Dendritic Cell Vaccine
go.drugbank.com/drugs/DB05477InvestigationalDendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells. … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.
Rimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant … Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295].
Fibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalIt works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.